Etanercept in combination with sulfasalazine, hydroxychloroquine, or gold in the treatment of rheumatoid arthritis

Journal of Rheumatology

Volumn 33, Issue 2, 2006, Pages 213-218

  O'Dell, James R ^a,b   Petersen, Kara ^a,c   Leff, Robert ^a,d   Palmer, William ^a,e   Schned, Eric ^a,f   Blakely, Kent ^a,g   Haire, Claire ^a,b   Fernandez, Ana ^a,d  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c UNIVERSITY OF IOWA   (United States)

^d Duluth Clinic   (United States)

^e Westroads Medical Group   (United States)

^f PARK NICOLLET CLINIC   (United States)

^g Platte Valley Medical Group   (United States)

Author keywords

Combination therapy; Etanercept; Gold; Hydroxychloroquine; Rheumatoid arthritis; Sulfasalazine

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLD; HYDROXYCHLOROQUINE; SALAZOSULFAPYRIDINE;

ADULT; AGED; ARTICLE; BLOOD DYSCRASIA; BREAST CANCER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DRUG EFFICACY; DRUG SAFETY; ECCHYMOSIS; FEMALE; GASTROENTERITIS; HUMAN; INJECTION SITE REACTION; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MYCOSIS; OPEN STUDY; OPTIC NEURITIS; OTITIS MEDIA; PERICARDITIS; PNEUMONIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEINURIA; RASH; RHEUMATOID ARTHRITIS; SEPSIS; SINUSITIS; TONGUE CANCER; TUBERCULOSIS; UPPER RESPIRATORY TRACT INFECTION; UROGENITAL TRACT INFECTION; WRIST DISEASE;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG THERAPY, COMBINATION; FEMALE; GOLD; HEALTH STATUS; HUMANS; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN G; INJECTIONS, INTRAMUSCULAR; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECEPTORS, TUMOR NECROSIS FACTOR; RECOMBINANT FUSION PROTEINS; SEVERITY OF ILLNESS INDEX; SULFASALAZINE; TREATMENT OUTCOME;

EID: 32144453291     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Choy EHS, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001;344:907-16.
2. Moreland LW. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 1999;130:478-86.
3. Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999;340:253-9.
4. Mikuls TR, O'Dell J. The changing face of rheumatoid arthritis therapy: results of serial surveys. Arthritis Rheum 2000;43:464-5.
5. O'Dell JR. Methotrexate use in rheumatoid arthritis. Rheum Dis Clin North Am 1997;23:779-96.
6. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
7. Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35.
8. Egger MJ, Huth DA, Ward JR, Reading JC, Williams HJ. Reduced joint count indices in the evaluation of rheumatoid arthritis. Arthritis Rheum 1985;28:613-9.
9. Olsen NJ, Stein CM. New drugs for rheumatoid arthritis. N Engl J Med 2004;350:2167-79.
10. Bathon JM, Martin RW, Fleischmann RM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000;343:1586-93.
11. O'Dell JR. Therapeutic strategies for rheumatoid arthritis. N Engl J Med 2004;350:2591-602.
12. Ellerin T, Rubin RH, Weinblatt ME. Infections and anti-tumor necrosis factor α therapy. Arthritis Rheum 2003;48:3013-22.
13. Ellerin T, Rubin RH, Weinblatt ME. Infections and anti-tumor necrosis factor-α therapy. Arthritis Rheum 2003;48:3013-22.
14. Cunnane G. Infections and biological therapy in rheumatoid arthritis. Best Pract Res Clin Rheumatol 2003;17:345-63.
15. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001;345:1098-104.
16. Gomez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD; BIOBADASER Group. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 2003;48:2122-7.
17. Brown SL. Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum 2002;46:3151-8.
18. Anker SD. How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH. Int J Cardiol 2002;86:123-30.
19. Mohan N. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum 2001;44:2862-9.
20. Slifman NR. Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents. Arthritis Rheum 2003;48:319-24.
21. Lee JH. Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept. Arthritis Rheum 2002;46:2565-70.